Ensartinib (X-396): what does it add for patients with ALK-rearranged NSCLC

Chin Clin Oncol. 2019 Oct;8(S1):S4. doi: 10.21037/cco.2018.10.12. Epub 2018 Nov 9.

Authors

Tianhong Li¹, Weijie Ma², Eddie C Tian²

Affiliations

¹ Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA; Veterans Affairs Northern California Health Care System, Mather, CA, USA. thli@ucdavis.edu.
² Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.

PMID: 30525756
DOI: 10.21037/cco.2018.10.12

No abstract available

Publication types

Editorial

MeSH terms

Anaplastic Lymphoma Kinase / metabolism*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Piperazines / pharmacology
Piperazines / therapeutic use*
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use*
Pyridazines / pharmacology
Pyridazines / therapeutic use*

Substances

Piperazines
Protein Kinase Inhibitors
Pyridazines
ALK protein, human
Anaplastic Lymphoma Kinase
ensartinib